Company Overview - Haili Biological's closing price on August 6 was 7.58 yuan, down 1.17%, with a rolling PE ratio of 26.75 times and a total market value of 4.97 billion yuan [1] - The company ranks 54th in the medical device industry, which has an average PE ratio of 53.93 times and a median of 37.81 times [1] Shareholder Information - As of March 31, 2025, Haili Biological had 31,505 shareholders, a decrease of 1,319 from the previous period, with an average holding value of 352,800 yuan and an average holding of 27,600 shares per shareholder [1] Business Segments - The main business segments of Shanghai Haili Biological Technology Co., Ltd. are in vitro diagnostic reagents (IVD) and oral tissue repair and regeneration materials, with key products including veterinary biological products and medical devices [1] Financial Performance - In the latest quarterly report for Q1 2025, the company achieved operating revenue of 61.79 million yuan, a year-on-year decrease of 12.11%, while net profit was 10.90 million yuan, a year-on-year increase of 393.11%, with a gross profit margin of 75.96% [1]

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 300871 | 回盛生物 | 23.52 | -5.24% | 27.00万 | 6.43 乙 | | 688098 | 申联生物 | 8.51 | -3.62% | 29.97万 | 2.57亿 | | 002868 | *ST绿康 | 26.30 | -1.50% | 1.45万 | 3804.68万 | | 603718 | 海利生物 | 7.58 | -1.17% | 9.42万 | 7168.65万 | | 688526 | 科前生物 | 16.96 | -0.88% | 3.74万 | 6337.08万 | | 839729 | 永顺生物 | 10.02 | -0.79% | 4.50万 | 4535.21万 | | 600195 | 中牧股份 | 7.61 | -0.78% | 9.50万 | 7231.88万 | | 838275 | 驱动力 | 10.02 | -0.60% | 1.65万 | 1640.86万 | | 6035 ...

Market Overview - The animal health sector increased by 1.46% on August 5, with Shenlian Biological leading the gains [1] - The Shanghai Composite Index closed at 3617.6, up 0.96%, while the Shenzhen Component Index closed at 11106.96, up 0.59% [1] Stock Performance - Shenlian Biological (688098) closed at 8.83, up 10.79% with a trading volume of 410,700 shares and a turnover of 348 million yuan [1] - Xianfeng Holdings (002141) closed at 3.81, up 4.10% with a trading volume of 732,700 shares and a turnover of 280 million yuan [1] - Jinhai Biological (002688) closed at 7.60, up 3.54% with a trading volume of 645,200 shares and a turnover of 487 million yuan [1] - Huisheng Biological (300871) closed at 24.82, up 1.85% with a trading volume of 260,400 shares and a turnover of 636 million yuan [1] Capital Flow - The animal health sector saw a net inflow of 138 million yuan from institutional investors, while retail investors experienced a net outflow of 127 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors showing confidence while retail investors are withdrawing [2] Individual Stock Capital Flow - Jinhai Biological had a net inflow of 40.62 million yuan from institutional investors, while retail investors had a net outflow of 29.52 million yuan [3] - Huisheng Biological saw a net inflow of 36.65 million yuan from institutional investors, but a significant outflow of 74.58 million yuan from retail investors [3] - Shenlian Biological experienced a net inflow of 18.09 million yuan from institutional investors, with retail investors withdrawing 20.78 million yuan [3]

Market Overview - The animal health sector increased by 0.65% on August 4, with BioShares leading the gains [1] - The Shanghai Composite Index closed at 3583.31, up 0.66%, while the Shenzhen Component Index closed at 11041.56, up 0.46% [1] Stock Performance - BioShares (600201) closed at 8.75, rising by 2.70% with a trading volume of 327,100 shares and a turnover of 280 million yuan [1] - Jinhe Biology (002688) closed at 7.34, up 2.51%, with a trading volume of 666,900 shares and a turnover of 485 million yuan [1] - Ruipu Biology (300119) closed at 21.58, increasing by 1.27%, with a trading volume of 72,800 shares and a turnover of 155 million yuan [1] - KQ Biology (688526) closed at 17.00, up 1.01%, with a trading volume of 29,600 shares and a turnover of 49.88 million yuan [1] - Other notable stocks include Dayu Biology (871970) at 10.40 (+0.97%) and Zeng Caike (603566) at 15.00 (+0.87%) [1] Capital Flow - The animal health sector saw a net inflow of 68.12 million yuan from institutional investors, while retail investors experienced a net outflow of 58.45 million yuan [2] - The main capital inflow and outflow for specific stocks include: - Jinhe Biology: 70.12 million yuan inflow from main investors, 33.36 million yuan outflow from retail investors [3] - BioShares: 15.45 million yuan inflow from main investors, 8.61 million yuan outflow from retail investors [3] - Shilian Biology (688098): 3.79 million yuan inflow from main investors, 27.89 million yuan outflow from retail investors [3]

Group 1 - The core viewpoint of the news is the significant rise in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to increased investor interest in related companies [1][2] - Companies such as Lide Man, Lianhuan Pharmaceutical, and Rejing Bio have seen substantial stock price increases, with Lide Man reaching a 20% limit up and Lianhuan Pharmaceutical achieving a nearly 10% increase [1][2] - The treatment plan emphasizes preventive measures against Chikungunya virus, including mosquito control and personal protective measures, highlighting the ongoing public health concern and the lack of available vaccines in China [1] Group 2 - Specific stock performance data shows Lide Man with a 20.03% increase, Lianhuan Pharmaceutical with a 9.98% increase, and Rejing Bio with a 9.25% increase, indicating strong market reactions [2] - Year-to-date performance reveals that Rejing Bio has surged by 244.50%, while Lianhuan Pharmaceutical has increased by 97.68%, showcasing the potential for continued growth in the sector [2] - Other companies such as Zhongsheng Pharmaceutical and Maiwei Niuwu also experienced notable gains, further indicating a broader trend in the virus prevention sector [1][2]

Group 1 - The core viewpoint of the news highlights a surge in virus prevention concept stocks, particularly in response to the release of the 2025 treatment plan for Chikungunya virus, which has led to significant stock price increases for several companies in the pharmaceutical sector [1][2] - Companies such as Lide Man and Lianhuan Pharmaceutical saw their stock prices rise by 20% and nearly 10% respectively, indicating strong market interest and potential investment opportunities in the sector [2] - The news also mentions that there is currently no available vaccine for the Chikungunya virus in China, which may drive demand for preventive measures and related pharmaceutical products [1] Group 2 - Specific stock performance data shows that Hotgen Biotech increased by over 9%, while Zhongsheng Pharmaceutical rose by over 7%, reflecting a broader trend of growth among virus prevention stocks [1][2] - The total market capitalization of Lide Man is reported at 4.597 billion, while Lianhuan Pharmaceutical stands at 5.538 billion, indicating substantial company valuations in the context of the current market dynamics [2] - Year-to-date performance shows that Hotgen Biotech has increased by 244.50%, suggesting a strong upward trend in investor confidence and market performance for this company [2]

证券之星消息，7月31日动物保健板块较上一交易日下跌0.43%，大禹生物领跌。当日上证指数报收于 3573.21，下跌1.18%。深证成指报收于11009.77，下跌1.73%。动物保健板块个股涨跌见下表： 从资金流向上来看，当日动物保健板块主力资金净流出1611.97万元，游资资金净流出6281.9万元，散户 资金净流入7893.87万元。动物保健板块个股资金流向见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300871 回盛生物 | | 6787.00万 | 7.85% | -4042.91万 | -4.68% | -2744.09万 | -3.17% | | 600201 | 生物股份 | 2619.98万 | 9.14% | -534.51万 | -1.86% | -2085.47万 | -7.28% | | 002868 *ST绿康 | | 940.97万 | 10.50% | -518.20 ...

证券之星消息，7月30日动物保健板块较上一交易日下跌0.46%，生物股份领跌。当日上证指数报收于 3615.72，上涨0.17%。深证成指报收于11203.03，下跌0.77%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 871970 | 大禹生物 | 10.98 | 7.65% | 7.08万 | 7555.51万 | | | 002868 | *ST绿康 | 26.73 | 4.99% | 2.78万 | 7294.48万 | | | 839729 | 永顺生物 | 10.02 | 1.83% | 4.19万 | 4168.45万 | | | 300871 | 回盛生物 | 22.22 | 1.37% | 16.18万 | | 3.63亿 | | 002688 | 金河生物 | 7.22 | 0.84% | 42.68万 | | 3.06亿 | | 688098 | 申联生物 | 6.90 | 0.73% | 10.01万 | 6919.84 ...

从资金流向上来看，当日动物保健板块主力资金净流出9984.08万元，游资资金净流出2164.17万元，散户 资金净流入1.21亿元。动物保健板块个股资金流向见下表： 证券之星消息，7月29日动物保健板块较上一交易日下跌0.5%，驱动力领跌。当日上证指数报收于 3609.71，上涨0.33%。深证成指报收于11289.41，上涨0.64%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 002868 | *ST绿康 | 25.46 | 2.91% | 2.25万 | | 5731.13万 | | 688098 | 申联生物 | 6.85 | 1.33% | 10.41万 | | 7137.24万 | | 603566 | 普莱柯 | 15.23 | 0.40% | 5.03万 | | 7579.24万 | | 002688 | 金河生物 | 7.16 | 0.14% | 36.15万 | | 2.59亿 | | 688526 | 科前生物 | 17.2 ...

Group 1: Industry Overview - The animal vaccine sector has seen a significant rise, with a market increase of approximately 2.91% as of July 16, 2023 [1] - The animal vaccine market is divided into two main categories: pet vaccines and livestock vaccines [1] - The pet vaccine market is experiencing rapid growth, driven by an increase in pet ownership and rising consumer spending, with the market size expected to exceed 345.3 billion yuan in 2024 [1] - The penetration rate of pet vaccines remains low, indicating substantial growth potential as pet owners become more health-conscious [1] Group 2: Livestock Vaccine Insights - In the context of the current "anti-involution" trend in pig farming, about 30% of pig companies have achieved over 50% of their annual output targets [2] - Major pig companies are implementing policies such as reducing breeding sows and controlling weight to enhance efficiency and disease prevention [2] - The demand for vaccines is expected to grow steadily alongside the development of the livestock industry, particularly due to the need for disease control against outbreaks like African swine fever [2] Group 3: Company Profiles - **Shengwu Co., Ltd.**: Focuses on the research, production, and sales of veterinary biological products, including vaccines for pigs, ruminants, poultry, and pets [2] - **Reap Bio**: A high-tech enterprise dedicated to providing solutions for disease prevention, treatment, and healthy breeding in the animal health industry [2] - **Kexing Pharmaceutical**: Engaged in animal vaccine research and development with a focus on zoonotic disease prevention [3] - **Puleke**: Specializes in the research, production, and sales of veterinary biological products and chemical drugs [4] - **Zhongmu Co., Ltd.**: Offers a wide range of vaccines, including poultry, veterinary, and special vaccines, with nearly 170 varieties [4] - **Shenlian Bio**: Primarily involved in the research, production, and sales of veterinary biological products, with pig vaccines as a major revenue source [4] - **Haizheng Pharmaceutical**: Its subsidiary focuses on the research, production, and sales of veterinary biological drugs [5] - **Haili Bio**: Engages in the research, production, and sales of animal vaccines [6]